Universe Pharmaceuticals (NASDAQ:UPC – Get Free Report) and Jaguar Animal Health (NASDAQ:JAGX – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, risk, institutional ownership, earnings, valuation and profitability.
Profitability
This table compares Universe Pharmaceuticals and Jaguar Animal Health’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Universe Pharmaceuticals | N/A | N/A | N/A |
| Jaguar Animal Health | -341.90% | -1,194.94% | -80.16% |
Institutional and Insider Ownership
0.2% of Universe Pharmaceuticals shares are held by institutional investors. Comparatively, 12.0% of Jaguar Animal Health shares are held by institutional investors. 57.4% of Universe Pharmaceuticals shares are held by insiders. Comparatively, 7.5% of Jaguar Animal Health shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Earnings & Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Universe Pharmaceuticals | $17.86 million | 0.07 | -$3.67 million | N/A | N/A |
| Jaguar Animal Health | $11.69 million | 0.18 | -$38.49 million | ($33.24) | -0.02 |
Universe Pharmaceuticals has higher revenue and earnings than Jaguar Animal Health.
Volatility and Risk
Universe Pharmaceuticals has a beta of 1.56, meaning that its stock price is 56% more volatile than the S&P 500. Comparatively, Jaguar Animal Health has a beta of 0.03, meaning that its stock price is 97% less volatile than the S&P 500.
Analyst Ratings
This is a summary of recent recommendations for Universe Pharmaceuticals and Jaguar Animal Health, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Universe Pharmaceuticals | 1 | 0 | 0 | 0 | 1.00 |
| Jaguar Animal Health | 1 | 0 | 1 | 0 | 2.00 |
Jaguar Animal Health has a consensus target price of $60.00, suggesting a potential upside of 10,868.92%. Given Jaguar Animal Health’s stronger consensus rating and higher probable upside, analysts plainly believe Jaguar Animal Health is more favorable than Universe Pharmaceuticals.
Summary
Universe Pharmaceuticals beats Jaguar Animal Health on 7 of the 12 factors compared between the two stocks.
About Universe Pharmaceuticals
Universe Pharmaceuticals INC, a pharmaceutical company, engages in the manufacture, marketing, distribution, and sale of traditional Chinese medicine derivative products in China. It offers products for the treatment of common chronic health conditions in the elderly for physical wellness and longevity; and cold and flu medications. The company also distributes and sells third-party producers, including biomedical drugs, medical instruments, traditional Chinese medicine pieces products, and dietary supplements. Its customers include pharmaceutical companies, hospitals, clinics, and drugstore chains. The company was incorporated in 2019 and is based in Ji’An, China. Universe Pharmaceuticals INC is a subsidiary of Sununion Holding Group Limited.
About Jaguar Animal Health
Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. The company's products include Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing NP-300, a second-generation antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California.
Receive News & Ratings for Universe Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Universe Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
